| +0.76 / +0.71%|
The 8 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 110.00, with a high estimate of 114.00 and a low estimate of 105.00. The median estimate represents a +1.96% increase from the last price of 107.89.
The current consensus among 9 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.